Any Edit,
Anywhere
We are pioneers with unlimited potential to cure genetic disease. We’re advancing a full spectrum of editing modalities to make any edit, anywhere, possible.
Our highly innovative, next-generation gene editing platform allows us to target any genomic sequence and develop life-changing therapies for the most challenging genetic disorders.
Life Edit
ElevateBio’s Gene Editing Business
We have one of the world’s largest and most diverse libraries of RNA-guided nucleases (RGNs) and base editors under one roof. The key advantage of our nuclease collection is in the diversity of Protospacer Adjacent Motifs (PAMs), which determine the DNA segments in the genome to which a nuclease can bind. Our broad range of PAMs increase the number of specific sites where therapeutically meaningful edits can be made, granting our nucleases access to virtually any region of the genome leading to unprecedented flexibility across a full spectrum of gene editing modalities, including double-strand breaks, base editing, and reverse transcriptase editing.
Life Edit is an integral part of the ElevateBio ecosystem of enabling technologies and end-to-end manufacturing capabilities dedicated to accelerating transformative genetic medicines. Combined, our technologies and expertise can enable an unprecedented breadth of advanced therapies.
Our Technology Platform
Our gene editing platform is available to make the entire spectrum of edits, from small insertions or deletions to rewriting DNA sequences.
Our Therapeutic Approaches
We can target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene editing therapies.
Partner with Life Edit
We are looking to form strategic partnerships with biotech and pharmaceutical companies to advance their life-changing and curative therapies. Our flexible partnership options include broad R&D collaborations, exclusive and non-exclusive licenses for specific assets, and strategic partnerships to access our technology platforms designed to accelerate the pipelines of our partners.
